Clinical Trial Update: Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety, reactogenicity, and immunogenicity of HB-502 and HB-501 versus placebo in people with HIV on suppressive ART; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• HB-501
• HB-502

Snippet

Sponsor: Hookipa Biotech GmbH | Conditions: Human Immunodeficiency Virus (HIV) Infection | Phase 1 | Status: TERMINATED